University of Florida Study Finds 85% of Commercial Kratom Products Have Inaccurate Labels

Why it matters

Consumers purchasing kratom products cannot rely on product labels to accurately reflect what they are ingesting, creating significant unrecognized risks — particularly when semisynthetic compounds like 7-hydroxymitragynine are present but undisclosed. This matters as the DEA considers scheduling 7-OH and as regulators debate consumer protection frameworks.

The big picture

The kratom market has expanded rapidly from traditional leaf powder to highly processed liquid shots, edibles, and semisynthetic formulations with limited regulatory oversight. FDA warnings about misleading claims have not resolved labeling inconsistencies. The University of Florida team used UPLC-MS/MS laboratory analysis to compare what companies list on product labels to what is actually present — a rigorous method rarely applied to the unregulated kratom market.

Key findings

• Researchers analyzed 44 commercially available kratom and kratom-derived products collected from online platforms and U.S. retail stores
• 85% of products had alkaloid concentrations that did not match their labeled content
• Some products listed a single alkaloid but laboratory analysis detected multiple undisclosed compounds
• Other products were missing alkaloids specifically listed on the label
• Products frequently contained pharmacologically active compounds including 7-OH and 3-dehydromitragynine that were not disclosed
• Findings published in Drug Testing and Analysis (July 14, 2026)

What they say

"Consumers should be able to trust that a product's label accurately reflects what's inside," said lead author Abhisheak Sharma, Ph.D. "Our findings show that stronger manufacturing standards, comprehensive testing and transparent labeling are needed to help people make informed decisions and reduce potential safety risks."

Bottom line

**85% of commercial kratom and kratom-derived products contain alkaloid profiles that do not match their labels — meaning consumers may unknowingly be ingesting potent opioid receptor agonists not listed anywhere on the package.**